Open-label period of the phase 3 LUNA3 trial in adults with previously treated immune thrombocytopenia: 46 of 198 (23%) given rilzabrutinib had stable platelet responses; 26% had treatment-related adverse events, most often grade 1–2 diarrhoea and nausea; 1% serious.
Open-label extensionn = 180
Kuter et al. Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial